

Stefanie D KrÄmer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2598724/publications.pdf>

Version: 2024-02-01

120
papers

3,780
citations

94269

37
h-index

161609

54
g-index

120
all docs

120
docs citations

120
times ranked

4898
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes of cerebral network activity after invasive stimulation of the mesencephalic locomotor region in a rat stroke model. <i>Experimental Neurology</i> , 2022, 347, 113884.	2.0	2
2	Kinetics of iron absorption from ferrous fumarate with and without galacto-oligosaccharides determined from stable isotope appearance curves in women. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 949-957.	2.2	5
3	Gut microbiome and circulating bacterial DNA (â€œblood microbiomeâ€) in a mouse model of total parenteral nutrition: Evidence of two distinct separate microbiotic compartments. <i>Clinical Nutrition ESPEN</i> , 2022, 49, 278-288.	0.5	5
4	Lipid emulsion rich in nâ€“3 polyunsaturated fatty acids elicits a pro-resolution lipid mediator profile in mouse tissues and in human immune cells. <i>American Journal of Clinical Nutrition</i> , 2022, 116, 786-797.	2.2	9
5	Pharmacogenetic Analysis of Voriconazole Treatment in Children. <i>Pharmaceutics</i> , 2022, 14, 1289.	2.0	6
6	Endothelial Barrier Disruption by Lipid Emulsions Containing a High Amount of N3 Fatty Acids (Omegaven) but Not N6 Fatty Acids (Intralipid). <i>Cells</i> , 2022, 11, 2202.	1.8	0
7	Novel Strategies to Prevent Total Parenteral Nutritionâ€Induced Gut and Liver Inflammation, and Adverse Metabolic Outcomes. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e1901270.	1.5	14
8	Nutritional Lipids and Mucosal Inflammation. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e1901269.	1.5	20
9	Choice of Lipid Emulsion Determines Inflammation of the Gutâ€Liver Axis, Incretin Profile, and Insulin Signaling in a Murine Model of Total Parenteral Nutrition. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000412.	1.5	8
10	In Vivo Imaging of Local Inflammation: Monitoring LPS-Induced CD80/CD86 Upregulation by PET. <i>Molecular Imaging and Biology</i> , 2021, 23, 196-207.	1.3	12
11	Permeation Studies across Symmetric and Asymmetric Membranes in Microdroplet Arrays. <i>Analytical Chemistry</i> , 2021, 93, 5137-5144.	3.2	11
12	Gentamicin Population Pharmacokinetics in Pediatric Patientsâ€A Prospective Study with Data Analysis Using the saemix Package in R. <i>Pharmaceutics</i> , 2021, 13, 1596.	2.0	2
13	SwissPK cdw â€“ A clinical data warehouse for the optimization of pediatric dosing regimens. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, , .	1.3	5
14	[11C]mHED PET follows a two-tissue compartment model in mouse myocardium with norepinephrine transporter (NET)-dependent uptake, while [18F]LMI1195 uptake is NET-independent. <i>EJNMMI Research</i> , 2020, 10, 114.	1.1	7
15	Neuroimaging with Radiopharmaceuticals Targeting the Glutamatergic System. <i>Chimia</i> , 2020, 74, 960-967.	0.3	5
16	Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor. <i>Journal of Nuclear Medicine</i> , 2019, 60, 259-266.	2.8	26
17	Synthesis and Structureâ€Affinity Relationship of Small Molecules for Imaging Human CD80 by Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8090-8100.	2.9	7
18	Preclinical Evaluation of Benzazepine-Based PET Radioligands (<i>R</i>)- and (<i>S</i>)- ^{11</sup>C-Me-NB1 Reveals Distinct Enantiomeric Binding Patterns and a Tightrope Walk Between GluN2B- and Î¶_{1</sub>-Receptorâ€Targeted PET Imaging. <i>Journal of Nuclear Medicine</i>, 2019, 60, 1167-1173.}}	2.8	30

#	ARTICLE	IF	CITATIONS
19	Chronic Nicotine Exposure Alters Metabotropic Glutamate Receptor 5: Longitudinal PET Study and Behavioural Assessment in Rats. <i>Neurotoxicity Research</i> , 2019, 36, 806-816.	1.3	8
20	Evaluation of ¹¹ C-Me-NB1 as a Potential PET Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk. <i>Journal of Nuclear Medicine</i> , 2018, 59, 698-703.	2.8	46
21	A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1041-1051.	3.3	16
22	Injected Human Muscle Precursor Cells Overexpressing PGC-1 α Enhance Functional Muscle Regeneration after Trauma. <i>Stem Cells International</i> , 2018, 2018, 1-11.	1.2	6
23	Physiologically Based Pharmacokinetic Modelling with Dynamic PET Data to Study the <i>In Vivo</i> Effects of Transporter Inhibition on Hepatobiliary Clearance in Mice. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-11.	0.4	7
24	Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [¹¹ C]RS-016 targeting CB2 in atherosclerosis. <i>Nuclear Medicine and Biology</i> , 2017, 47, 31-43.	0.3	26
25	GABAA receptor subtypes in the mouse brain: Regional mapping and diazepam receptor occupancy by in vivo [18F]flumazenil PET. <i>NeuroImage</i> , 2017, 150, 279-291.	2.1	16
26	Kinetics of lipid bilayer permeation of a series of ionisable drugs and their correlation with human transporter-independent intestinal permeability. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 104, 150-161.	1.9	19
27	CD80 Is Upregulated in a Mouse Model with Shear Stress-Induced Atherosclerosis and Allows for Evaluating CD80-Targeting PET Tracers. <i>Molecular Imaging and Biology</i> , 2017, 19, 90-99.	1.3	19
28	Synthesis, Radiolabeling, and Biological Evaluation of 5-Hydroxy-2- ¹⁸ F-fluoroalkyl-tryptophan Analogues as Potential PET Radiotracers for Tumor Imaging. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5324-5340.	2.9	18
29	Enhanced sensitivity to drugs of abuse and palatable foods following maternal overnutrition. <i>Translational Psychiatry</i> , 2016, 6, e911-e911.	2.4	58
30	Synthesis and Pharmacological Evaluation of [¹¹ C]Granisetron and [¹⁸ F]Fluoropalonosetron as PET Probes for 5-HT ₃ Receptor Imaging. <i>ACS Chemical Neuroscience</i> , 2016, 7, 1552-1564.	1.7	18
31	Discovery of a fluorinated 4-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2. <i>Journal of Neurochemistry</i> , 2016, 138, 874-886.	2.1	31
32	Noninvasive PET Imaging and Tracking of Engineered Human Muscle Precursor Cells for Skeletal Muscle Tissue Engineering. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1467-1473.	2.8	12
33	Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis. <i>EJNMMI Research</i> , 2016, 6, 1.	1.1	33
34	When barriers ignore the "rule-of-five". <i>Advanced Drug Delivery Reviews</i> , 2016, 101, 62-74.	6.6	52
35	Quantitative aspects of drug permeation across in vitro and in vivo barriers. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 87, 30-46.	1.9	11
36	Accurate molecular imaging of small animals taking into account animal models, handling, anaesthesia, quality control and imaging system performance. <i>EJNMMI Physics</i> , 2015, 2, 31.	1.3	37

#	ARTICLE	IF	CITATIONS
37	Evaluation of the Radiolabeled Boronic Acid-Based FAP Inhibitor MIP-1232 for Atherosclerotic Plaque Imaging. <i>Molecules</i> , 2015, 20, 2081-2099.	1.7	37
38	Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 554-564.	2.6	56
39	Preclinical evaluation and test-retest studies of [¹⁸ F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 128-137.	3.3	27
40	Synthesis and pharmacological evaluation of ¹¹ C-labeled piperazine derivative as a PET probe for sigma-2 receptor imaging. <i>Nuclear Medicine and Biology</i> , 2015, 42, 399-405.	0.3	7
41	Discovery of a High Affinity and Selective Pyridine Analog as a Potential Positron Emission Tomography Imaging Agent for Cannabinoid Type 2 Receptor. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4266-4277.	2.9	55
42	Ex vivo differential phase contrast and magnetic resonance imaging for characterization of human carotid atherosclerotic plaques. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 1425-1434.	0.7	8
43	Quantitative positron emission tomography of ¹⁸ F-mGluR5 in rat brain with [¹⁸ F]PSS232 at minimal invasiveness and reduced model complexity. <i>Journal of Neurochemistry</i> , 2015, 133, 330-342.	2.1	23
44	Development and Evaluation of Novel PET Tracers for Imaging Cannabinoid Receptor Type 2 in Brain. <i>Chimia</i> , 2014, 68, 208.	0.3	8
45	Synthesis and Preliminary Evaluation of a 2-Oxoquinoline Carboxylic Acid Derivative for PET Imaging the Cannabinoid Type 2 Receptor. <i>Pharmaceuticals</i> , 2014, 7, 339-352.	1.7	17
46	Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability. <i>Nuclear Medicine and Biology</i> , 2014, 41, 562-569.	0.3	43
47	Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules. <i>International Journal of Cardiology</i> , 2014, 174, 503-515.	0.8	32
48	Passive Lipoidal Diffusion and Carrier-Mediated Cell Uptake Are Both Important Mechanisms of Membrane Permeation in Drug Disposition. <i>Molecular Pharmaceutics</i> , 2014, 11, 1727-1738.	2.3	106
49	Synthesis and Biological Evaluation of ¹⁸ F-Labeled Fluoroethoxy Tryptophan Analogues as Potential PET Tumor Imaging Agents. <i>Molecular Pharmaceutics</i> , 2014, 11, 3839-3851.	2.3	21
50	Synthesis and preliminary biological evaluation of O-2((2-[¹⁸ F]fluoroethyl)methylamino)ethyltyrosine ([¹⁸ F]FEMAET) as a potential cationic amino acid PET tracer for tumor imaging. <i>Amino Acids</i> , 2014, 46, 1947-1959.	1.2	10
51	Cell-Free Microfluidic Determination of P-glycoprotein Interactions with Substrates and Inhibitors. <i>Pharmaceutical Research</i> , 2014, 31, 3415-3425.	1.7	16
52	Imaging Tumour ATBO,+ Transport Activity by PET with the Cationic Amino Acid O-2((2-[¹⁸ F]fluoroethyl)methyl-amino)ethyltyrosine. <i>Molecular Imaging and Biology</i> , 2014, 16, 412-420.	1.3	24
53	¹⁸ F-MRS glucose mapping and ¹⁸ F-PET joining forces: re-evaluation of the lumped constant in the rat brain under isoflurane anaesthesia. <i>Journal of Neurochemistry</i> , 2014, 129, 672-682.	2.1	9
54	A liposomal fluorescence assay to study permeation kinetics of drug-like weak bases across the lipid bilayer. <i>Journal of Controlled Release</i> , 2014, 173, 102-109.	4.8	49

#	ARTICLE	IF	CITATIONS
55	Imaging Atherosclerotic Plaque Inflammation via Folate Receptor Targeting Using a Novel ¹⁸ F-Folate Radiotracer. <i>Molecular Imaging</i> , 2014, 13, 7290.2013.00074.	0.7	35
56	Imaging atherosclerotic plaque inflammation via folate receptor targeting using a novel ¹⁸ F-folate radiotracer. <i>Molecular Imaging</i> , 2014, 13, 1-11.	0.7	19
57	Radiolabeling and <i>in vitro</i> / <i>in vivo</i> evaluation of N-(1-(adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinolin-3-carboxamide) as a PET probe for imaging cannabinoid type 2 receptor. <i>Journal of Neurochemistry</i> , 2013, 126, 616-624.	1.0	10
58	FDG kinetic modeling in small rodent brain PET: optimization of data acquisition and analysis. <i>EJNMMI Research</i> , 2013, 3, 61.	1.1	10
59	Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of 1f2 receptors. <i>European Journal of Medicinal Chemistry</i> , 2013, 69, 920-930.	2.6	42
60	Studies toward the Development of New Silicon-Containing Building Blocks for the Direct ¹⁸ F-Labeling of Peptides. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7552-7563.	2.9	26
61	Synthesis and <i>in vitro</i> / <i>in vivo</i> pharmacological evaluation of [¹¹ C]-ThioABP, a novel radiotracer for imaging mGluR5 with PET. <i>MedChemComm</i> , 2013, 4, 520.	3.5	3
62	Radiosynthesis and Preclinical Evaluation of 3- ¹⁸ F-fluorofolic Acid: A Novel PET Radiotracer for Folate Receptor Targeting. <i>Bioconjugate Chemistry</i> , 2013, 24, 205-214.	1.8	43
63	Design, Synthesis, and Initial Evaluation of a High Affinity Positron Emission Tomography Probe for Imaging Matrix Metalloproteinases 2 and 9. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4912-4920.	2.9	31
64	Synthesis and biological evaluation of ¹⁸ F-labeled fluoropropyl tryptophan analogs as potential PET probes for tumor imaging. <i>European Journal of Medicinal Chemistry</i> , 2013, 70, 768-780.	2.6	30
65	Synthesis and <i>In Vitro</i> Evaluation of E- and Z-Geometrical Isomers of PSS232 as Potential Metabotropic Glutamate Receptors Subtype 5 (mGlu5) Binders. <i>Synthesis</i> , 2013, 45, 1877-1885.	1.2	8
66	Brain Glucose Transport and Phosphorylation Under Acute Insulin-Induced Hypoglycemia in Mice: An ¹⁸ F-FDG PET Study. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2153-2160.	2.8	11
67	Characterization of Different Osteosarcoma Phenotypes by PET Imaging in Preclinical Animal Models. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1362-1368.	2.8	21
68	Quantification of Brain Glucose Metabolism by ¹⁸ F-FDG PET with Real-Time Arterial and Image-Derived Input Function in Mice. <i>Journal of Nuclear Medicine</i> , 2013, 54, 132-138.	2.8	54
69	Synthesis and preclinical evaluation of a new C-6 alkylated pyrimidine derivative as a PET imaging agent for HSV1-tk gene expression. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 3, 71-84.	1.0	3
70	Expression Profiles of Metabolic Enzymes and Drug Transporters in the Liver and along the Intestine of Beagle Dogs. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1603-1611.	1.7	30
71	Development of [¹⁸ F]-PSS223 as a PET Tracer for Imaging of Metabotropic Glutamate Receptor Subtype 5 (mGluR5). <i>Chimia</i> , 2012, 66, 201.	0.3	9
72	5-(2- ¹⁸ F-Fluoroethoxy)-l-Tryptophan as a Substrate of System L Transport for Tumor Imaging by PET. <i>Journal of Nuclear Medicine</i> , 2012, 53, 434-442.	2.8	45

#	ARTICLE	IF	CITATIONS
73	Evaluation of fluorescence anisotropy to assess drug-lipid membrane partitioning. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 71, 219-227.	1.4	20
74	[¹⁸ F]Fluoro-Deoxy-Glucose Folate: A Novel PET Radiotracer with Improved in Vivo Properties for Folate Receptor Targeting. <i>Bioconjugate Chemistry</i> , 2012, 23, 805-813.	1.8	65
75	Synthesis and evaluation of a C-6 alkylated pyrimidine derivative for the in vivo imaging of HSV1-TK gene expression. <i>Nuclear Medicine and Biology</i> , 2012, 39, 235-246.	0.3	6
76	Synthesis and Evaluation of Novel \pm -Fluorinated (E)-3-((6-Methylpyridin-2-yl)ethynyl)cyclohex-2-enone-O-methyl Oxime (ABP688) Derivatives as Metabotropic Glutamate Receptor Subtype 5 PET Radiotracers. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7154-7162.	2.9	7
77	Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. <i>Drug Discovery Today</i> , 2012, 17, 905-912.	3.2	125
78	Radiofluorinated histamine H3 receptor antagonist as a potential probe for in vivo PET imaging: Radiosynthesis and pharmacological evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2889-2896.	1.4	12
79	Synthesis, radiolabelling and in vitro and in vivo evaluation of a novel fluorinated ABP688 derivative for the PET imaging of metabotropic glutamate receptor subtype 5. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 2, 14-28.	1.0	11
80	In vitro and in vivo evaluation of [¹⁸ F]-FDEGPECO as a PET tracer for imaging the metabotropic glutamate receptor subtype 5 (mGluR5). <i>NeuroImage</i> , 2011, 56, 984-991.	2.1	16
81	Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial <i>Pseudomonas aeruginosa</i> O11 pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1110-1116.	1.3	58
82	Anti-VEGF antibody treatment accelerates polycystic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, F773-F783.	1.3	28
83	Particle size and activation threshold: a new dimension of danger signaling. <i>Blood</i> , 2010, 115, 4533-4541.	0.6	103
84	Syntheses and pharmacological characterization of novel thiazole derivatives as potential mGluR5 PET ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 6044-6054.	1.4	19
85	Lipid membrane interactions of indacaterol and salmeterol: Do they influence their pharmacological properties?. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 38, 533-547.	1.9	84
86	Cholesterol-Mediated Activation of P-Glycoprotein: Distinct Effects on Basal and Drug-Induced ATPase Activities. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 1905-1918.	1.6	35
87	The Biochemistry of Drug Metabolism - An Introduction. <i>Chemistry and Biodiversity</i> , 2009, 6, 591-684.	1.0	58
88	Lipid Bilayer Permeation of Drug-Like Compounds. <i>Chemistry and Biodiversity</i> , 2009, 6, 1900-1916.	1.0	52
89	The Biochemistry of Drug Metabolism - An Introduction. <i>Chemistry and Biodiversity</i> , 2009, 6, 1477-1660.	1.0	29
90	Interaction kinetics of salmeterol with egg phosphatidylcholine liposomes by surface plasmon resonance. <i>Analytical Biochemistry</i> , 2009, 385, 215-223.	1.1	12

#	ARTICLE	IF	CITATIONS
91	Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis. <i>Molecular and Cellular Biochemistry</i> , 2008, 316, 155-161.	1.4	29
92	The Biochemistry of Drug Metabolism – An Introduction. <i>Chemistry and Biodiversity</i> , 2008, 5, 2171-2336.	1.0	102
93	The Biochemistry of Drug Metabolism – An Introduction. <i>Chemistry and Biodiversity</i> , 2008, 5, 2465-2578.	1.0	51
94	Dynamics and Cleavability at the β -Cleavage Site of APP(684-726) in Different Lipid Environments. <i>Biophysical Journal</i> , 2008, 95, 1460-1473.	0.2	15
95	Permeation of a β -heptapeptide derivative across phospholipid bilayers. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007, 1768, 2726-2736.	1.4	45
96	The Biochemistry of Drug Metabolism - An Introduction. <i>Chemistry and Biodiversity</i> , 2007, 4, 257-405.	1.0	139
97	The Biochemistry of Drug Metabolism – An Introduction. <i>Chemistry and Biodiversity</i> , 2007, 4, 2031-2122.	1.0	68
98	Comparing the Lipid Membrane Affinity and Permeation of Drug-like Acids: The Intriguing Effects of Cholesterol and Charged Lipids. <i>Pharmaceutical Research</i> , 2007, 24, 1457-1472.	1.7	54
99	P-Glycoprotein in Proteoliposomes with Low Residual Detergent: The Effects of Cholesterol. <i>Pharmaceutical Research</i> , 2007, 24, 1993-2004.	1.7	22
100	The Biochemistry of Drug Metabolism – An Introduction. <i>Chemistry and Biodiversity</i> , 2006, 3, 1053-1101.	1.0	79
101	Comparison of Permeation through Phosphatidylcholine Bilayers of N-Dipicolinyl- β - and β -Oligopeptides. <i>Chemistry and Biodiversity</i> , 2006, 3, 1181-1201.	1.0	14
102	Role of drug efflux carriers in the healthy and diseased brain. <i>Annals of Neurology</i> , 2006, 60, 489-498.	2.8	60
103	Isolated Rafts from Adriamycin-Resistant P388 Cells Contain Functional ATPases and Provide an Easy Test System for P-glycoprotein-Related Activities. <i>Pharmaceutical Research</i> , 2005, 22, 449-457.	1.7	10
104	EFFECT OF THE MODULATION OF THE MEMBRANE LIPID COMPOSITION ON THE LOCALIZATION AND FUNCTION OF P-GLYCOPROTEIN IN MDR1-MDCK CELLS. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2005, 41, 207.	0.7	50
105	Permeation of Aromatic Carboxylic Acids across Lipid Bilayers: The pH-Partition Hypothesis Revisited. <i>Biophysical Journal</i> , 2005, 89, 1802-1811.	0.2	68
106	β -Tocopherol influences the lipid membrane affinity of desipramine in a pH-dependent manner. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 21, 313-321.	1.9	17
107	LIPIDS IN BLOOD – BRAIN BARRIER MODELS IN VITRO I: THIN-LAYER CHROMATOGRAPHY AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY FOR THE ANALYSIS OF LIPID CLASSES AND LONG-CHAIN POLYUNSATURATED FATTY ACIDS. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2002, 38, 557.	0.7	26
108	LIPIDS IN BLOOD – BRAIN BARRIER MODELS IN VITRO II: INFLUENCE OF GLIAL CELLS ON LIPID CLASSES AND LIPID FATTY ACIDS. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2002, 38, 566.	0.7	27

#	ARTICLE	IF	CITATIONS
109	Physicochemical properties in pharmacokinetic lead optimization. <i>Il Farmaco</i> , 2001, 56, 145-148.	0.9	38
110	P-Glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope. <i>European Journal of Pharmaceutical Sciences</i> , 2000, 12, 69-77.	1.9	42
111	Permeation studies in vitro and in vivo of potential radiopharmaceuticals with affinity to neuro receptors. <i>Pharmaceutical Research</i> , 2000, 17, 754-760.	1.7	2
112	Cell cultures as tools in biopharmacy. <i>European Journal of Pharmaceutical Sciences</i> , 2000, 11, S51-S60.	1.9	131
113	Absorption prediction from physicochemical parameters. <i>Pharmaceutical Science & Technology Today</i> , 1999, 2, 373-380.	0.7	82
114	Towards the predictability of drug-lipid membrane interactions: the pH-dependent affinity of propranolol to phosphatidylinositol containing liposomes. <i>Pharmaceutical Research</i> , 1998, 15, 739-744.	1.7	77
115	MDCK cell cultures as an epithelial in vitro model: cytoskeleton and tight junctions as indicators for the definition of age-related stages by confocal microscopy. <i>Pharmaceutical Research</i> , 1998, 15, 964-971.	1.7	60
116	Considerations on the potentiometric log P determination. <i>Pharmaceutical Research</i> , 1998, 15, 1310-1313.	1.7	29
117	Free fatty acids cause pH-dependent changes in drug-lipid membrane interactions around physiological pH. <i>Pharmaceutical Research</i> , 1997, 14, 827-832.	1.7	42
118	The pH-dependence in the partitioning behaviour of (RS)-[3H]propranolol between MDCK cell lipid vesicles and buffer. <i>Pharmaceutical Research</i> , 1996, 13, 1851-1855.	1.7	34
119	Lipid Bilayers in ADME: Permeation Barriers and Distribution Compartments. , 0, , 203-220.		3
120	Biological Models to Study Blood-Brain Barrier Permeation. , 0, , 127-153.		6